Baltimore Business Journal

Alba Therapeutics Corp. tapped a former executive at Columbia's Martek Biosciences to head its live tissue pharmacology and toxicology efforts.

Linda M. Arterburn will be the Baltimore biotech's senior director of in vivo (live tissue) pharmacology and toxicology. She previously led clinical research and scientific affairs at Martek, where she helped secure regulatory approvals that allowed the company's products to be used in infant formula.

Alba, a privately held company, is working to create treatments for celiac disease, an intestinal disorder, and other autoimmune diseases.
Arterburn, earned a doctoral degree in pharmacology and molecular sciences from the Johns Hopkins University School of Medicine and a bachelor's degree in biochemistry from the University of Wisconsin.